Evidence map›Paper›PMID 38002427›Full record

ArticleBioengineering (Basel, Switzerland)2023

A Nanostructured Protein Filtration Device for Possible Use in the Treatment of Alzheimer's Disease-Concept and Feasibility after In Vivo Tests.

Thomas Gabriel Schreiner, Manuel Menéndez-González, Maricel Adam, Bogdan Ovidiu Popescu, Andrei Szilagyi, Gabriela Dumitrita Stanciu, Bogdan Ionel Tamba, Romeo Cristian Ciobanu

Open access · goldAbstract read
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Thomas Gabriel SchreinerFaculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 050474 Bucharest, Romania.ORCID 0000-0002-4495-4004
Manuel Menéndez-GonzálezDepartment of Medicine, University of Oviedo, 33006 Oviedo, Spain.ORCID 0000-0002-5218-0774
Maricel AdamDepartment of Electrical Measurements and Materials, Faculty of Electrical Engineering and Information Technology, Gheorghe Asachi Technical University of Iasi, 700050 Iasi, Romania.ORCID 0000-0001-8158-4375
Bogdan Ovidiu PopescuFaculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 050474 Bucharest, Romania.ORCID 0000-0003-4826-2598
Andrei SzilagyiAdvanced Research and Development Center for Experimental Medicine (CEMEX), "Grigore T. Popa" University of Medicine and Pharmacy, Universitatii Str., No. 16, 700155 Iasi, Romania.ORCID 0009-0009-4734-4509
Gabriela Dumitrita StanciuAdvanced Research and Development Center for Experimental Medicine (CEMEX), "Grigore T. Popa" University of Medicine and Pharmacy, Universitatii Str., No. 16, 700155 Iasi, Romania.ORCID 0000-0003-4440-9628
Bogdan Ionel TambaFaculty of Medicine, University of Medicine and Pharmacy "Gr. T. Popa", 700115 Iasi, Romania.ORCID 0000-0001-9868-1999
Romeo Cristian CiobanuDepartment of Electrical Measurements and Materials, Faculty of Electrical Engineering and Information Technology, Gheorghe Asachi Technical University of Iasi, 700050 Iasi, Romania.
Grigore T. Popa University of Medicine and Pharmacy · ROCarol Davila University of Medicine and Pharmacy · ROGheorghe Asachi Technical University of Iași · ROUniversidad de Oviedo · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlzheimer's disease (AD), along with other neurodegenerative disorders, remains a challenge for clinicians, mainly because of the incomplete knowledge surrounding its etiology and inefficient therapeutic options. Considering the central role of amyloid beta (Aβ) in the onset and evolution of AD, Aβ-targeted therapies are among the most promising research directions. In the context of decreased Aβ elimination from the central nervous system in the AD patient, the authors propose a novel therapeutic approach based on the "Cerebrospinal Fluid Sink Therapeutic Strategy" presented in previous works. This article aims to demonstrate the laborious process of the development and testing of an effective nanoporous ceramic filter, which is the main component of an experimental device capable of filtrating Aβ from the cerebrospinal fluid in an AD mouse model.

methodsFirst, the authors present the main steps needed to create a functional filtrating nanoporous ceramic filter, which represents the central part of the experimental filtration device. This process included synthesis, functionalization, and quality control of the functionalization, which were performed via various spectroscopy methods and thermal analysis, selectivity measurements, and a biocompatibility assessment. Subsequently, the prototype was implanted in APP/PS1 mice for four weeks, then removed, and the nanoporous ceramic filter was tested for its filtration capacity and potential structural damages.

resultsIn applying the multi-step protocol, the authors developed a functional Aβ-selective filtration nanoporous ceramic filter that was used within the prototype. All animal models survived the implantation procedure and had no significant adverse effects during the 4-week trial period. Post-treatment analysis of the nanoporous ceramic filter showed significant protein loading, but no complete clogging of the pores.

conclusionsWe demonstrated that a nanoporous ceramic filter-based system that filtrates Aβ from the cerebrospinal fluid is a feasible and safe treatment modality in the AD mouse model. The presented prototype has a functional lifespan of around four weeks, highlighting the need to develop advanced nanoporous ceramic filters with anti-biofouling properties to ensure the long-term action of this therapy.

Indexed as

Alzheimer’s diseasebiocompatibilitycerebrospinal fluidnanoporous ceramic filterneurodegenerative diseaseprotein filtrationscanning electron microscopy

Identifiers

PMID38002427
PMCPMC10669467
OpenAlexW4388567794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.